Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neridronic acid - Abiogen Pharma

Next Previous
Drug Profile

Neridronic acid - Abiogen Pharma

Alternative Names: AHBP; AHDP; AHHexBP; Aminohexane diphosphonate; Aminohexane-bisphosphonate; Attila; Neridronate; Neridronate-sodium; Nerixia

Latest Information Update: 02 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Istituto Gentili
  • Developer Abiogen Pharma; Austin Pain Associates; Grunenthal; Lee's Pharmaceutical; Shire Pharmaceuticals Group
  • Class Analgesics; Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reflex sympathetic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteitis deformans; Osteogenesis imperfecta
  • Registered Complex regional pain syndromes
  • Phase III Osteoporosis
  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 02 Jan 2023 Phase III development for Osteoporosis is ongoing in Italy (IV) (EudraCT2018-003505-26)
  • 02 Jan 2023 No development reported - Phase-III for Complex regional pain syndromes in Asia (IV)
  • 02 Jan 2023 No development reported - Phase-III for Complex regional pain syndromes in European Union (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top